Clinical Trial Update: Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

View source ↗

Summary

This clinical trial update describes a real-world study evaluating SKB264 as monotherapy or in combination for recurrent or metastatic HER2-negative breast canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• SKB264

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: HER2-negative Breast Cancer, Recurrence | Status: NOT_YET_RECRUITING